Victory Capital Management Inc. Has $10.17 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Victory Capital Management Inc. decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,649 shares of the biopharmaceutical company's stock after selling 2,148 shares during the period. Victory Capital Management Inc.'s holdings in Alnylam Pharmaceuticals were worth $10,166,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of ALNY. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. boosted its position in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $28,000. Colonial Trust Co SC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $35,000. Finally, Washington Trust Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 61 shares during the period. Institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ALNY shares. Truist Financial began coverage on shares of Alnylam Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $385.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. BMO Capital Markets boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. Citigroup lifted their target price on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $347.75.

Alnylam Pharmaceuticals Stock Up 0.2%

Shares of ALNY stock traded up $0.81 during trading on Friday, hitting $328.81. 666,674 shares of the company were exchanged, compared to its average volume of 911,887. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The firm has a market capitalization of $42.87 billion, a price-to-earnings ratio of -157.33 and a beta of 0.23. The business's 50-day simple moving average is $310.69 and its 200 day simple moving average is $274.03. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. Alnylam Pharmaceuticals's revenue was up 20.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.